Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non–Small-Cell Lung CancerAbdul Rafeh Naqash, Hirva Mamdani, Amin H. Nassar et al.|JCO Precision Oncology|2024Cited by 5
<i>STK11</i>/<i>TP53</i> co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.Abdul Rafeh Naqash, Hirva Mamdani, Charalampos S. Floudas et al.|Journal of Clinical Oncology|2021Cited by 3